John Douthit, DO
Family Medicine · Thornton, CONPI 1144304767
Payments from drug & device makers
Across 176 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$880
- Lilly USA, LLC$515
- AstraZeneca$297
- GSK$148
- Amgen$116
- Bayer$114
- plus $840 from 19 others
What the payments were for
- Food & beverage$2,899100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $880 |
| Lilly USA, LLC | 34 | $515 |
| AstraZeneca | 20 | $297 |
| GSK | 8 | $148 |
| Amgen | 5 | $116 |
| Bayer | 7 | $114 |
| Pfizer | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Boehringer Ingelheim | 5 | $90 |
| Novo Nordisk | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Gilead | 3 | $66 |
| Amarin Pharma, Inc. | 3 | $57 |
| Eisai Inc. | 2 | $44 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Verona Pharma, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 2 | $27 |
| Exact Sciences | 1 | $27 |
| Cequr Corporation | 1 | $23 |
| Novartis | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Merck | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Abbott | 1 | $12 |
How this compares
$2,911 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 162 | $189,370 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $65,954 |
| JardianceEmpagliflozin | 44 | $54,921 |
| TrulicityDulaglutide | 35 | $50,756 |
| FarxigaDapagliflozin Propanediol | 36 | $37,908 |
| VraylarCariprazine Hcl | 22 | $34,991 |
| XareltoRivaroxaban | 25 | $32,190 |
| JanuviaSitagliptin Phosphate | 24 | $29,454 |
| EliquisApixaban | 36 | $27,043 |
| EntrestoSacubitril/Valsartan | 22 | $26,617 |
| Spiriva RespimatTiotropium Bromide | 28 | $24,496 |
| MyrbetriqMirabegron | 23 | $23,048 |
| TradjentaLinagliptin | 14 | $20,795 |
| Spiriva HandihalerTiotropium Bromide | 15 | $13,223 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $10,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $515 | $240,127197 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat, Combivent Respimat | $90 | $116,233113 claims |
| GSKTrelegy Ellipta | $148 | $65,95475 claims |
| AstraZenecaFarxiga, Symbicort | $297 | $43,07948 claims |
| AbbVieVraylar | $880 | $34,99122 claims |
| MerckJanuvia, Dulera | $15 | $33,63536 claims |
| PfizerEliquis | $91 | $27,04336 claims |
| NovartisEntresto | $23 | $26,61722 claims |
| Astellas Pharma US IncMyrbetriq | $27 | $23,04823 claims |
| Novo NordiskLevemir | $83 | $4,33714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Thornton
- Kenneth HahnThornton$20K
- Philip RosenblumThornton$18K
- Kent SchreiberThornton$17K
- Suzanne NashThornton$15K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.